Eugit Therapeutics
Enabling Tissue Targeting of Therapies
About
Eugit Therapeutics targets the issue of non-specific drugs that cause toxicity and clinical trial failures, affecting millions with tissue-specific inflammatory diseases. TAGHOME delivers drugs with precision to diseased tissues using T cell receptors, enhancing safety and improving efficacy. Our initial focus is on the 3.1 million U.S. individuals with Inflammatory Bowel Disease, aiming to initiate clinical trials within two years.
Cofounded by George Church (Harvard) and funded by Y Combinator (S22).
Topics
- Location
- San Francisco, CA, United States
- Team size
- 2 employees
- YC batch
- Summer 2022
- Status
- Active
- Stage
- Early stage
